Soleno Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company was acquired and taken private on May 18, 2026, ending its public stock trading.
Quarterly earnings show how the company performed in early 2026 before its acquisition closed.
Soleno stopped pursuing European regulatory approval for its Prader-Willi syndrome treatment.
A buyer began offering to purchase Soleno shares, leading to the acquisition completed in May.
Updated company rules to reflect Delaware law changes and improve stockholder communication processes.
A new leader joined the company on February 25, 2026, affecting management decisions.
Annual earnings show total revenue, expenses, and cash position heading into the acquisition.
Stocky reads Soleno Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Soleno Therapeutics, Inc.'s most recent tracked filing was a 8-K on 18 May 2026: Merger completed, company becomes wholly owned subsidiary.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.